32nd Annual J.P.Morgan Healthcare Conference, San Francisco
Jefferies 2013 Global Healthcare Conference, Nov 20, 2013, London
Bank of America Merrill Lynch Global Healthcare Conference, Sept 12, 2013, London
Rodman & Renshaw Annual Global Investment Conference, Sept 9, 2013, New York
J.P. Morgan Cazenove European Healthcare Conference, June 24, 2013, London
Jefferies 2013 Global Healthcare Conference, June 3-6, New York
Kempen&Co 6th Life Sciences & Healthcare Conference, April 23, 2013, Amsterdam
Bank of America Merrill Lynch, March 22, 2013, Copenhagen
Carnegie Healthcare Seminar, March 12, 2013, Stockholm
BIO-Europe Spring, March 11-13, 2013, Barcelona
Credit Suisse Global Healthcare Conference, March 6, 2013, London
31st Annual J.P. Morgan Healthcare Conference, Jan 10, 2013, San Francisco
SEB Enskilda Nordic Seminar, Jan 8-9, Copenhagen
Rodman & Renshaw Annual Global Investment Conference, Sept 11, 2012
Active Biotech Capital Markets Day, June 14, 2012
Jefferies 2012 Global Healthcare Conference, June 5
Jefferies 2011 Global Healthcare Conference, June 8, 2011
2011 Genitourinary Cancers Symposium, Feb 17-19 - view poster here:
Phase II study of tasquinimod in chemotherapy naїve patients with metastatic castrate-resistant prostate cancer (CRPC) ― safety and efficacy analysis including subgroups
UBS Global Life Sciences Conference, September 22, 2010
Rodman & Renshaw Annual Global Investment Conference Healthcare, September 13-15, 2010
Capital Markets Day in Stockholm, June 10, 2010
The ANYARA project - Combining tumor-targeted superantigens with anti-CTLA-4
Keystone Symposia "Molecular and Cellular Biology of Immune Escape in Cancer" held in Keystone, Colorado, USA, February 7-12.
UBS Global Life Sciences Conference held September 21-23, 2009 at the Grand Hyatt, Grand Central in New York City, US.
Rodman & Renshaw 11th Annual Healthcare Conference on Friday, September 11 2009 at the New York Palace Hotel in New York City, US.
10th Annual Congress of the European League against Rheumatism (EULAR), an international event for specialists in the field of rheumatology, held in Copenhagen June 10-13, 2009.
A Phase I, Dose-Escalation Study to Evaluate the Tolerability of ABR-215757 in patients with Systemic Lupus Erythematosus (SLE)
Active Biotech published data regarding a molecular target for the quinoline (Q) compounds in the scientific journal PLoS Biology, Volume 7, Issue 4, April 2009 (which is an open access journal and the full article is available at http://biology.plosjournals.org). Three of Active Biotech's projects (laquinimod, 57-57 and TASQ) belong to this chemical class of compounds.
Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides
IBC's 6th Annual Antibody Therapeutics held in San Diego, US on December 9-11 2008
A fusion protein between a 5T4 binding antibody fragment and an engineered superantigen (ANYARA) is a targeted immunotherapy effective alone and in combination with other cancer therapies